Blueprint Medicines Corp
blueprintmedicines.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 1, 2025. Its latest SEC filing is a SCHEDULE 13G from Aug 14, 2025.
10-Q for Q1 FY2025, filed May 1, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells AYVAKIT for systemic mastocytosis and certain gastrointestinal tumors, and develops medicines for other mast-cell, inflammatory and cancer conditions for patients.
10-K for FY2024, filed Feb 13, 2025We are a global, fully-integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by…View ↗
We continue to build a mast cell disease franchise, based on our deep understanding of mast cell biology and the KIT pathway. We are…View ↗
AYVAKIT®/AYVAKYT® (avapritinib)View ↗
Avapritinib is also approved in the U.S. under the brand name AYVAKIT for the treatment of adults with unresectable or metastatic GIST…View ↗
How Did They Make Money?
Most revenue comes from AYVAKIT/AYVAKYT product sales to specialty distributors and specialty pharmacies; those sales count when delivered. Other revenue includes upfront license fees when rights transfer and payments for research services as the work is performed.
10-K for FY2024, filed Feb 13, 2025For the year ended December 31, 2024, our revenue primarily consisted of product sales of AYVAKIT/AYVAKYT as well as some collaboration…View ↗
The Company generated product revenue primarily from sales of AYVAKIT in the U.S and sales of AYVAKYT in the European Union to a limited…View ↗
Product revenue is recognized when the customer takes control of the product, typically upon delivery to the customer. Product revenue is…View ↗
Exclusive Licenses. If the license to the Company’s intellectual property is determined to be distinct from the other promises or…View ↗
Research and Development Services. The promises under the Company’s collaboration agreements may include research and development services…View ↗
$508.8M
-
10-K for FY2024, filed Feb 13, 2025
$508.8M ↗
Who Were Their Customers?
The company sells AYVAKIT/AYVAKYT to specialty distributors and specialty pharmacies; they resell it or dispense it directly to patients.
10-K for FY2024, filed Feb 13, 2025The Company generated product revenue primarily from sales of AYVAKIT in the U.S and sales of AYVAKYT in the European Union to a limited…View ↗
Did Revenues Turn Into Profits?
No. It lost $67.1M in FY2024.
10-K for FY2024, filed Feb 13, 2025
−$212MView ↗
10-K for FY2024, filed Feb 13, 2025
−$67.1MView ↗
10-K for FY2024, filed Feb 13, 2025
−$197.2MView ↗
How Were They Changing?
-
Jul 18, 2025
Sanofi completed its acquisition of Blueprint Medicines
Shareholders received approximately $9.1 billion in cash plus rights to possible additional payments.
Sources
8-K, filed Jul 18, 2025
The aggregate consideration paid by Purchaser to purchase all of the Shares in the Offer and to complete the Merger was approximately $9.1…View ↗
-
Jun 2, 2025
Sanofi agreed to acquire Blueprint Medicines
The offer included $129.00 per share in cash and possible extra payments tied to BLU-808 milestones.
Sources
8-K, filed Jun 2, 2025
Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately…View ↗
-
May 1, 2025
Blueprint raised its 2025 AYVAKIT revenue guidance
The company raised its forecast to $700 million to $720 million in global net product revenue.
Sources
8-K, filed May 1, 2025
-- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 --View ↗
Shrank. Revenue fell 36% in 4 years, from $793.7M in FY2020 to $508.8M in FY2024, about 11% a year.
AYVAKIT's expanded use
The older report described avapritinib for non-advanced systemic mastocytosis as still in development; the latest report describes it as approved for indolent systemic mastocytosis in the U.S. and Europe.
10-K for FY2021, filed Feb 17, 2022 10-K for FY2024, filed Feb 13, 2025We are commercializing avapritinib for the treatment of advanced SM and indolent SM. The FDA approved avapritinib under the brand name…View ↗
A wider allergy and inflammation focus
The older report framed the pipeline around cancer and blood disorders; the latest also centers allergy and inflammation, including programs for chronic urticaria and other mast-cell conditions.
10-K for FY2021, filed Feb 17, 2022 10-K for FY2024, filed Feb 13, 2025We are a global precision therapy company that is inventing life-changing medicines for people with cancer and blood disorders. Applying an…View ↗
GAVRETO assets sold
The older report described developing and commercializing pralsetinib as GAVRETO with partners; the latest says the related assets were sold to Rigel.
10-K for FY2021, filed Feb 17, 2022 10-K for FY2024, filed Feb 13, 2025We are developing and commercializing pralsetinib for the treatment of RET fusion-positive non-small cell lung cancer, or NSCLC, and for…View ↗
We have had two approved precision therapies, AYVAKIT/AYVAKYT and GAVRETO. While we have been commercializing AYVAKIT in the U.S. and…View ↗
Who Did They Compete With?
Competes with Novartis, Alys Pharmaceuticals, Cogent Biosciences, Hoth Therapeutics, AB Science, Allakos, Celldex Therapeutics, Invea Therapeutics, Telios Pharma, ARIAD Pharmaceuticals, AROG Pharmaceuticals, AstraZeneca, Deciphera Pharmaceuticals, Exelixis, Ningbo Tai Kang Medical Technology, Xencor, Genentech, Alivexis, Amgen, and Eli Lilly
10-K for FY2024, filed Feb 13, 2025AYVAKIT/AYVAKYT and elenestinib (BLU-263) face competition for advanced SM from Novartis AG’s midostaurin and imatinib, and may face…View ↗
Loading...
